http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MY-172303-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7ff94ac24a903db7b576ff6c8c7ddfde
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2603-40
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-222
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C69-013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01N63-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-225
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C69-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-618
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-606
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C69-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01N43-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
filingDate 2008-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72d6bd5362902edd049b19e99cd3ef7c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92e7de8571e4887ff0d3da4e99f6ced1
publicationDate 2019-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber MY-172303-A
titleOfInvention Compositions and methods of use of phorbol esters
abstract Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of cytopathic diseases. Cytopathic diseases may be caused by a variety means such as viral infections like HIV and AIDS in a mammalian subject. The methods and compositions of the invention are effective for inhibiting de novo HIV infection, upregulating viral expression from latent provirus, inhibiting HIV-induced cytopathic effects, down regulating the HIV receptor, increasing Thi cytokine expression, and decreasing Th2 cytokine expression. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent such as those used in HAART protocols or therapeutic agents used to treat opportunistic infections due to HIV in mammalian subjects.
priorityDate 2007-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID27924
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID442070
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419584009
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419553129

Total number of triples: 33.